XML 51 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Segment Information (Tables)
 3 Months Ended
Sep. 30, 2015
Segment Reporting [Abstract]  
Net Revenue and Segment EBITDA
The following tables include net revenue and Segment EBITDA during the three months ended September 30, 2015 and September 30, 2014:
 
Three Months Ended  
 September 30,
(Dollars in millions)
2015
 
2014
Oral Technologies
 
 
 
Net revenue
$
247.7

 
$
261.1

Segment EBITDA
51.1

 
57.7

Medication Delivery Solutions
 
 
 
Net revenue
55.7

 
56.9

Segment EBITDA
7.8

 
9.9

Development and Clinical Services
 
 
 
Net revenue
122.9

 
103.1

Segment EBITDA
27.2

 
21.4

   Inter-segment revenue elimination
(3.3
)
 
(2.8
)
   Unallocated Costs (1)
(13.9
)
 
(52.4
)
Combined Totals:
 
 
 
Net revenue
$
423.0

 
$
418.3

 
 
 
 
EBITDA from continuing operations
$
72.2

 
$
36.6


(1)
Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:
 
Three Months Ended  
 September 30,
(Dollars in millions)
2015
 
2014
Impairment charges and gain/(loss) on sale of assets
$
(1.2
)
 
$
—

Equity compensation
$
(2.5
)
 
$
(1.5
)
Restructuring and other special items (2)
(2.0
)
 
(4.5
)
Noncontrolling interest
0.2

 
0.4

Other income/(expense), net (3)
(0.6
)
 
(41.3
)
Non-allocated corporate costs, net
(7.8
)
 
(5.5
)
Total unallocated costs
$
(13.9
)
 
$
(52.4
)


(2)
Segment results do not include restructuring and certain acquisition-related costs.
(3)
Amounts primarily relate to foreign currency translation gains and losses during all periods presented. Prior period amounts primarily relate to the expense associated with the termination of the sponsor advisory services agreement of $29.8 million in connection with the IPO, expenses related to financing transactions of $20.6 million, offset by an acquisition-related gain of $7.0 million.
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA
Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations:
 
Three Months Ended  
 September 30,
(Dollars in millions)
2015
 
2014
Earnings/(loss) from continuing operations
$
8.9

 
$
(20.3
)
Depreciation and amortization
35.5

 
35.0

Interest expense, net
22.7

 
35.5

Income tax (benefit)/expense
4.9

 
(14.0
)
Noncontrolling interest
0.2

 
0.4

EBITDA from continuing operations
$
72.2

 
$
36.6
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements: 
(Dollars in millions)
September 30, 
 2015
 
June 30, 
 2015
Assets
 
 
 
Oral Technologies
$
2,426.3

 
$
2,477.3

Medication Delivery Solutions
242.7

 
247.8

Development and Clinical Services
688.5

 
703.2

Corporate and eliminations
(301.1
)
 
(282.9
)
Total assets
$
3,056.4

 
$
3,145.4